Related Experiment Videos
Alzheimer's disease. Cholinergic therapy and beyond
1Geriatric Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 20892-1275, USA.
Summary
Alzheimer's disease (AD) therapy is advancing beyond genetics and beta-amyloid to include FDA-approved cholinesterase inhibitors and novel neuroprotective agents. The field is moving towards effective combination therapies for AD treatment.
Area of Science:
- Neurology
- Pharmacology
- Gerontology
Background:
- Alzheimer's disease (AD) research traditionally focused on genetics and beta-amyloid.
- Limited therapeutic options existed previously for AD.
- A shift towards broader therapeutic strategies is occurring.
Purpose of the Study:
- To provide a clinical framework for current and emerging Alzheimer's disease therapies.
- To highlight the evolution of AD treatment beyond the cholinergic hypothesis.
Main Methods:
- Review of current FDA-approved treatments for AD.
- Analysis of emerging therapeutic agents and approaches.
- Discussion of combination therapy strategies for AD.
Main Results:
- Two cholinesterase inhibitors are FDA-approved for AD.
- New therapeutic avenues include neuroprotective agents and pathogenesis interference.
- Combination approaches represent the future of AD therapy.
Conclusions:
- The clinical era of viable cholinergic therapies for AD has begun.
- Therapeutic strategies are expanding beyond the central cholinergic hypothesis.
- Effective combination therapies are on the horizon for Alzheimer's disease management.